Insider · CIK 0001647994
Barry J. Simon
Files at IBRX (ImmunityBio, Inc.). First filing Jan 21, 2026, latest Oct 6, 2026.
In brief
Barry J. Simon files SEC Form 4 as director at IBRX (ImmunityBio, Inc.). Since Jan 21, 2026, Barry J. Simon has reported 0 open-market buys worth $0 and 6 open-market sells worth $4.4M, the latest filed on Oct 6, 2026.
A track record needs three past buys with six months of prices behind them; Barry J. Simon has 0, so none is measured yet.
The newest scored trade: sold $269k of IBRX on Oct 5, 2026, filed Oct 6, 2026, scored 16 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 6 sells worth $4.4M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
IBRX: ImmunityBio, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 16Weak | ImmunityBio, Inc. | $269k 25,000 shares | -1% | - | |
| 22Weak | ImmunityBio, Inc. | $197k 25,000 shares | -1% | +294% from low-32% from high | |
| 6Weak | ImmunityBio, Inc. | $165k 23,033 shares | -1% | +268% from low-37% from high | |
| 27Weak | ImmunityBio, Inc. | $901k 75,000 shares | -3% | +511% from low0% from high | |
| 13Weak | ImmunityBio, Inc. | $1.8M 175,000 shares | -6% | +360% from low0% from high | |
| 28Weak | ImmunityBio, Inc. | $1.1M 151,967 shares | -5% | +243% from low0% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 5, 2026 | IBRX ImmunityBio, Inc. | 560,000 0.05% of outstanding | $7.7M | Oct 5, 2026 | none |
| Jun 4, 2026 | IBRX ImmunityBio, Inc. | 268,033 0.03% of outstanding | $2.9M | Jun 4, 2026 | none |
| Jan 20, 2026 | IBRX ImmunityBio, Inc. | 571,967 0.06% of outstanding | $5.9M | Jan 20, 2026 | none |
Transactions
Every row this insider has filed, 16 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | IBRX ImmunityBio, Inc. | SOpen-market sale Common Stock10b5-1 | -25,000 | $10.75 | $269k | 2,777,788 | 7 d ago |
| Jun 24, 2026 | IBRX ImmunityBio, Inc. | SOpen-market sale Common Stock10b5-1 | -25,000 | $7.88 | $197k | 2,802,788 | Jun 26, 2026 |
| Jun 4, 2026 | IBRX ImmunityBio, Inc. | SOpen-market sale Common Stock10b5-1 | -23,033 | $7.18 | $165k | 2,827,788 | Jun 5, 2026 |
| Feb 24, 2026 | IBRX ImmunityBio, Inc. | SOpen-market sale Common Stock10b5-1 | -75,000 | $12.01 | $901k | 2,850,821 | Feb 26, 2026 |
| Feb 20, 2026 | IBRX ImmunityBio, Inc. | SOpen-market sale Common Stock10b5-1 | -10,000 | $9.25 | $93k | 3,081,604 | Feb 24, 2026 |
| Feb 22, 2026 | IBRX ImmunityBio, Inc. | MOption exercise Common Stock10b5-1 | +15,243 | $0.00 | $0 | 3,096,847 | Feb 24, 2026 |
| Feb 22, 2026 | IBRX ImmunityBio, Inc. | FTax withholding Common Stock10b5-1 | -6,026 | $8.70 | $52k | 3,090,821 | Feb 24, 2026 |
| Feb 23, 2026 | IBRX ImmunityBio, Inc. | SOpen-market sale Common Stock10b5-1 | -165,000 | $10.25 | $1.7M | 2,925,821 | Feb 24, 2026 |
| Feb 22, 2026 | IBRX ImmunityBio, Inc. | MOption exercise Restricted Stock Unitsderivative10b5-1 | -15,243 | $0.00 | $0 | 15,245 | Feb 24, 2026 |
| Jan 20, 2026 | IBRX ImmunityBio, Inc. | SOpen-market sale Common Stock10b5-1 | -76,967 | $6.54 | $503k | 3,166,604 | Jan 21, 2026 |
| Jan 20, 2026 | IBRX ImmunityBio, Inc. | SOpen-market sale Common Stock10b5-1 | -75,000 | $7.88 | $591k | 3,091,604 | Jan 21, 2026 |
| Feb 22, 2025 | IBRX ImmunityBio, Inc. | MOption exercise Common Stock | +15,243 | $0.00 | $0 | 3,249,024 | Feb 25, 2025 |
| Feb 22, 2025 | IBRX ImmunityBio, Inc. | FTax withholding Common Stock | -5,453 | $3.42 | $19k | 3,243,571 | Feb 25, 2025 |
| Feb 22, 2025 | IBRX ImmunityBio, Inc. | MOption exercise Restricted Stock Unitsderivative | -15,243 | $0.00 | $0 | 30,488 | Feb 25, 2025 |
| Jan 22, 2025 | IBRX ImmunityBio, Inc. | MOption exercise Common Stock | +110,020 | $2.00 | $220k | 3,233,781 | Jan 24, 2025 |
| Jan 22, 2025 | IBRX ImmunityBio, Inc. | MOption exercise Stock Option (right to buy)derivative | -110,020 | $0.00 | $0 | 0 | Jan 24, 2025 |
Questions about Barry J. Simon
Answered from the filings on this page, as of the latest one.
Is Barry J. Simon buying or selling?
In the last 12 months Barry J. Simon reported 0 open-market buys worth $0 and 6 open-market sells worth $4.4M on SEC Form 4; the latest was sold $269k of IBRX on Oct 5, 2026. Grants, option exercises and tax withholding are not counted.
How did Barry J. Simon's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Barry J. Simon has 0.
Where does Barry J. Simon file Form 4?
Barry J. Simon has filed Form 4 at IBRX (ImmunityBio, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.